Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.
Ryan K. Shields(Antibiotic Research UK), Brian A. Potoski(University of Pittsburgh), Ghady Haidar, Binghua Hao(University of Pittsburgh Medical Center), Yohei Doi, Liang Chen(Rutgers, The State University of New Jersey), Ellen G. Press, Barry N. Kreiswirth(Rutgers, The State University of New Jersey), Cornelius J. Clancy(VA Pittsburgh Healthcare System), M. Hong Nguyen(Antibiotic Research UK)
Cited by 424Open Access
Abstract
Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.
Related Papers
No related papers found
Powered by citation graph analysis